Merrimack Pharmaceuticals, Inc. (MACK) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Merrimack Pharmaceuticals, Inc.

MACK

NASDAQ

Unprofitable

Unprofitable

224M

Biotechnology

Next Earning date - 31 Oct 2024

224M

Biotechnology

Next Earning date - 31 Oct 2024

15.14USD

0.01 ( 0.10%)

Relative Strenght

100

Volume Buzz

405%

Earning Acce

No

Dist 52w H.

5%

Quote Panel

Updated October 27, 2024

1W % 1M % 3M % 1Y 62038.08 %

Key Metrics

Market Cap
223.97M
Shares Outstanding
14.79M
Share in Float
9.66M
Dividende
15.1

Earning Date
31 Oct 2024
Price Target
15.145
Average Volume
182633
Beta
1.416

Range
11.53-15.89
Industry
Biotechnology
Website
https://www.merrimack.com
Sector
Healthcare

Fundamentals

N/A

P/E Ratio

0.00x

P/S Ratio

0.99x

P/B Ratio

0.0

Debt/Equity

0.0%

Net Margin

$-0.1

EPS

How MACK compares to sector?

P/E Ratio

Relative Strength

MACK

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

No Data Available

Analyst rating

No Data Available

Last analyst upgrade/downgrade

No Data Available

Earnings Growth

YoY

Current

Estimates

Q2.22

N/A

-0.04
vs -0.06

Q3.22

N/A

-0.03
vs -0.04

Q4.22

N/A

-0.03
vs -0.03

Q1.23

N/A

-0.02
vs -0.04

Q2.23

N/A

-0.03
vs -0.04

Q3.23

N/A

-0.02
vs -0.03

Q4.23

N/A

-0.01
vs -0.03

Q1.24

N/A

-0.03
vs -0.02

Q3.24

+6813%

1.34
vs -0.02

Q4.24

+15514%

1.54
vs -0.01

Sales Growth

YoY

Current

Estimates

Q4.21

NA

NA vs NA

Q1.22

NA

NA vs NA

Q2.22

NA

NA vs NA

Q3.22

NA

NA vs NA

Q4.22

NA

-445000.00 vs NA

Q1.23

NA

NA vs NA

Q2.23

NA

NA vs NA

Q3.23

NA

NA vs NA

Q4.23

+100%

NA vs -445000

Q1.24

NA

NA vs NA

Return on Equity

QoQ

Q2.22

-3%

-0.03
vs -0.01

Q3.22

-2%

-0.02
vs -0.03

Q4.22

-3%

-0.03
vs -0.02

Q1.23

0%

-0.00
vs -0.03

Q2.23

-2%

-0.02
vs -0.00

Q3.23

-1%

-0.01
vs -0.02

Q4.23

-1%

-0.01
vs -0.01

Q1.24

-11%

-0.11
vs -0.01

Institutionnal Ownership

QoQ

Q2.22

40

40
vs 42

-5%

Q3.22

42

42
vs 40

5%

Q4.22

53

53
vs 42

26%

Q1.23

55

55
vs 53

4%

Q2.23

66

66
vs 55

20%

Q3.23

69

69
vs 66

5%

Q4.23

73

73
vs 69

6%

Q1.24

71

71
vs 73

-3%

Earnings Growth

Latest News

MACK

businesswire.com

16 hours ago

Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock

MACK

businesswire.com

16 hours ago

Merrimack Receives $225 Million Milestone Payment from Ipsen

MACK

businesswire.com

16 hours ago

Merrimack Reports Full Year 2023 Financial Results

MACK

businesswire.com

16 hours ago

Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

MACK

businesswire.com

16 hours ago

Merrimack Reports Third Quarter 2023 Financial Results

MACK

businesswire.com

17 hours ago

Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution

New Feature Coming Soon, Stay Tuned!

Shape

Shape